CagriSema (cagrilintide + semaglutide) was submitted to the FDA in late 2025 with a decision expected in 2026
Phase 2 dose-finding data The phase 2 trial tested cagrilintide at 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg, and 4.5 mg weekly
Hair loss is only rampant today because modern toxins and stress keep the scalp in a hostile environment so DHT's damage hits way harder
GHK-Cu signals fibroblasts (the skin's collagen-producing cells) to upregulate the production of types I, II, and III collagen, as well as elastin, glycosaminoglycans, and decorin
"The influence of BPC 157 on nitric oxide synthesis in various models of inflammation and organ injury." Life Sci
There have been postmarketing reports of acute renal failure (unspecified) and worsening of chronic renal failure, which sometimes has required hemodialysis in patients treated with GLP-1 receptor agonists